Rigel Pharmaceuticals (RIGL) Current Assets (2010 - 2026)

Rigel Pharmaceuticals has reported Current Assets for 17 years, with the latest figure at $234.0 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 59.68% year-over-year to $234.0 million; the trailing twelve-month figure through Mar 2026 stood at $234.0 million (up 59.68% YoY), and the FY2025 full-year result was $240.2 million, up 77.77% from the prior year.
• Current Assets for Q1 2026 stood at $234.0 million, down from $240.2 million in the prior quarter.
• The five-year high for Current Assets was $240.2 million in Q4 2025, with the low at $92.5 million in Q1 2024.
• Average Current Assets over 5 years is $136.9 million, with a median of $115.9 million recorded in 2022.
• Year-over-year, Current Assets slumped 35.45% in 2022 and soared 101.87% in 2025.
• Tracing RIGL's Current Assets over 5 years: stood at $115.9 million in 2022, then decreased by 14.35% to $99.3 million in 2023, then jumped by 36.1% to $135.1 million in 2024, then surged by 77.77% to $240.2 million in 2025, then retreated by 2.56% to $234.0 million in 2026.
• The last three Current Assets figures came in at $234.0 million (Q1 2026), $240.2 million (Q4 2025), and $214.9 million (Q3 2025), per Business Quant data.

Peer Comparison